REGENXBIO Inc. (RGNX) analyst actions
Rating and price-target actions on RGNX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the RGNX overview →
4 measured RGNX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against REGENXBIO Inc. (RGNX) And Encourages Shareholders to Reach Out | Press release | -0.38% | +1.39% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against REGENXBIO Inc. (RGNX) And Encourages Stockholders to Reach Out | Press release | +0.19% | -0.63% | |
| REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program | Press release | +1.37% | +0.55% | |
| REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA | Press release | -2.88% | -8.64% |
Keep exploring
More RGNX: earnings → · SEC filings → · RGNX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AB Corporate Bond ETF (EYEG) | 700 | 0.00% | 44% |
| STEMLINE THERAPEUTICS (STML) | 697 | +0.08% | 51% |
| ALDER BIOPHARMACEUTICALS INC (ALDR) | 693 | -0.21% | 45% |
| DIGIRAD (DRAD) | 692 | 0.00% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.